Vertex Pharmaceutical

Feb 05, 07
	NEW STORY
09:15 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Feb 02, 07
	NEW STORY
08:30 ET	Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011
Feb 01, 07
16:12 ET	Vertex Pharmaceuticals Reports 2006 Financial Results
Jan 24, 07
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference
Jan 16, 07
09:15 ET	Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2006 Financial Results Conference Call and Webcast
Jan 08, 07
08:30 ET	Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference
Jan 03, 07
16:05 ET	Vertex Pharmaceuticals Announces Webcast of Its Presentation at the 25th Annual JPMorgan Healthcare Conference
Dec 21, 06
08:30 ET	Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias
Dec 13, 06
06:55 ET	Vertex Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950)
Dec 11, 06
07:40 ET	Vertex Pharmaceuticals Added to NASDAQ-100 Index
07:31 ET	Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders
Nov 09, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Upcoming Investor Conferences
Oct 31, 06
16:24 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Upcoming Investor Conferences
Oct 27, 06
07:04 ET	New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting
Oct 26, 06
16:01 ET	Vertex Pharmaceuticals Reports Third Quarter 2006 Financial Results
Oct 09, 06
09:15 ET	Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast
Sep 20, 06
16:15 ET	Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Sep 18, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Sep 14, 06
19:41 ET	Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Sep 11, 06
16:08 ET	Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Sep 08, 06
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference
Sep 05, 06
16:18 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the NewsMakers in the Biotech Industry Conference
Aug 17, 06
12:45 ET	Head-to-Head Study Comparing LEXIVA(R) (Fosamprenavir Calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet
Aug 13, 06
10:44 ET	Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens
Aug 03, 06
08:40 ET	Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
Aug 02, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual Canaccord Adams Summer Seminar
Jul 26, 06
16:02 ET	Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results
Jul 06, 06
16:05 ET	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2006 Financial Results Conference Call and Webcast
Jun 30, 06
08:01 ET	Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
08:00 ET	Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Jun 16, 06
16:06 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Jun 09, 06
09:15 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences
May 26, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
May 23, 06
07:30 ET	Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
May 21, 06
14:30 ET	Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
May 17, 06
08:31 ET	Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis
May 16, 06
08:30 ET	GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
May 12, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bank of America Health Care Conference 2006
May 11, 06
16:00 ET	Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
May 04, 06
09:15 ET	Vertex Pharmaceuticals to Webcast its 2006 Annual Meeting of Stockholders
Apr 29, 06
12:00 ET	Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients
Apr 28, 06
09:15 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Apr 26, 06
08:31 ET	New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950
Apr 25, 06
16:06 ET	Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
Apr 05, 06
16:05 ET	Vertex Pharmaceuticals Announces the Date of its First Quarter 2006 Financial Results Conference Call and Webcast
07:00 ET	Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
Mar 23, 06
08:30 ET	Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF
Mar 20, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2006 Bear Stearns Biotech West Coast Confab
Mar 08, 06
16:05 ET	Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis
Mar 02, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Feb 23, 06
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference
Feb 07, 06
16:03 ET	Vertex Pharmaceuticals Reports 2005 Financial Results
00:01 ET	Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program
Feb 03, 06
16:05 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Jan 18, 06
09:15 ET	Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2005 Financial Results Conference Call and Webcast
Jan 12, 06
08:30 ET	Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research
Jan 09, 06
07:04 ET	Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
07:02 ET	VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon
Jan 04, 06
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 24th Annual JPMorgan Healthcare Conference
Dec 16, 05
14:15 ET	GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir
Dec 13, 05
07:59 ET	GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
Dec 08, 05
08:09 ET	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
Dec 07, 05
08:31 ET	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
Dec 05, 05
08:31 ET	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
Nov 28, 05
18:16 ET	Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $95.0 Million of its Convertible Senior Subordinated Notes Due 2011
Nov 18, 05
09:00 ET	FDA Approves Updated Labeling for LEXIVA
Nov 11, 05
15:17 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at Credit Suisse First Boston's Health Care Conference
08:30 ET	AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor
Nov 09, 05
09:15 ET	Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX- 950 Presentations at the Upcoming AASLD Meeting
Oct 31, 05
16:59 ET	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the MASS Opportunities Biotechnology Investment Conference 2005
Oct 26, 05
16:12 ET	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results
Oct 04, 05
16:30 ET	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis
09:15 ET	Vertex Pharmaceuticals Announces the Date of its Third Quarter 2005 Financial Results Conference Call and Webcast
Oct 03, 05
08:04 ET	New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track
Sep 21, 05
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 UBS Global Life Sciences Conference
Sep 09, 05
08:12 ET	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Sep 07, 05
09:15 ET	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
Jul 28, 05
16:20 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual Adams Harkness Summer Seminar
Jul 27, 05
16:17 ET	Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results
Jul 26, 05
16:01 ET	Lewis C. Cantley, Ph.D., Named to Vertex Pharmaceuticals' Scientific Advisory Board
11:00 ET	Long-Term Safety Data of LEXIVA/r in HIV Patients Co-Infected with Hepatitis
11:00 ET	Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy
Jul 19, 05
08:32 ET	FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385)
Jul 12, 05
16:05 ET	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2005 Financial Results Conference Call and Webcast
Jun 23, 05
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns Boston Biotech Confab
Jun 17, 05
09:00 ET	Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680
Jun 15, 05
08:30 ET	Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Jun 13, 05
16:05 ET	Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Jun 10, 05
08:30 ET	Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702
Jun 09, 05
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs' Twenty-Sixth Annual Global Healthcare Conference
Jun 07, 05
19:02 ET	Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
May 31, 05
16:01 ET	Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 17, 05
12:45 ET	Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study
May 11, 05
13:00 ET	Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
May 10, 05
07:06 ET	Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study
May 05, 05
09:15 ET	Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders
Apr 29, 05
10:01 ET	New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir
10:00 ET	New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium
Apr 27, 05
16:06 ET	Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences
Apr 26, 05
16:08 ET	Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update
Apr 04, 05
09:15 ET	Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast
Mar 11, 05
09:15 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference
Feb 23, 05
17:05 ET	Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals
Feb 18, 05
08:04 ET	Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences
Feb 15, 05
07:56 ET	Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer
Feb 09, 05
16:03 ET	Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance
Feb 08, 05
07:57 ET	Vertex Pharmaceuticals Announces Two Senior Management Changes
Feb 03, 05
07:58 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Feb 02, 05
07:57 ET	Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast
Jan 10, 05
08:04 ET	Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference
Jan 06, 05
08:03 ET	Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
Jan 05, 05
10:00 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference
Dec 15, 04
15:00 ET	Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART
Dec 07, 04
07:55 ET	Vertex Pharmaceuticals Announces the Appointment of Kerry Reinertsen, Ph.D., as Vice President of Corporate and Business Development
Dec 02, 04
07:55 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Harris Nesbitt Focus on Healthcare Conference 2004
Nov 23, 04
07:55 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Life Sciences Conference
Nov 17, 04
08:31 ET	Study Reveals Widespread Use of Antacids and Other Heartburn Medications Among HIV Patients
Nov 15, 04
07:55 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the CSFB 2004 Healthcare Conference
Nov 10, 04
07:55 ET	Novartis Selects Drug Candidate for Clinical Development from Protein Kinase Research Collaboration with Vertex
Nov 08, 04
08:03 ET	Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
08:01 ET	Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine
Nov 01, 04
16:05 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the MASS Opportunities Biotechnology Investment Conference 2004
08:06 ET	Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
Oct 25, 04
16:09 ET	Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update
Oct 18, 04
08:05 ET	Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients
Oct 05, 04
16:05 ET	Vertex Pharmaceuticals Announces the Date of its Third Quarter 2004 Financial Results Conference Call and Webcast
Sep 22, 04
07:55 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the UBS Global Life Sciences Conference
Sep 17, 04
16:42 ET	Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange
Sep 13, 04
18:55 ET	Vertex Pharmaceuticals Announces Issuance of Convertible Senior Subordinated Notes Due 2011 in Exchange for $79.3 Million of its Convertible Subordinated Notes Due 2007
Sep 09, 04
08:00 ET	Vertex Pharmaceuticals Announces the Appointment of Matthew W. Emmens to its Board of Directors
Sep 08, 04
07:55 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 17th Annual Healthcare Conference
Sep 07, 04
08:03 ET	Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C
Jul 26, 04
16:00 ET	Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update
Jul 16, 04
04:00 ET	GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV
Jul 13, 04
08:01 ET	Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC
Jul 12, 04
08:03 ET	Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI) - Experienced Patients
Jul 08, 04
16:00 ET	48-Week Efficacy Comparison Of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published In AIDS
Jun 30, 04
08:02 ET	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2004 Financial Results Conference Call and Webcast
Jun 22, 04
07:55 ET	Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer
Jun 15, 04
16:05 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Third Annual Needham Biotechnology Conference
Jun 14, 04
08:12 ET	Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries
Jun 09, 04
07:58 ET	Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis
Jun 08, 04
07:55 ET	Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
07:50 ET	Investigational Protease Inhibitor 640385 (VX-385) from GSK and Vertex Indicates Activity Against HIV, Including Protease Inhibitor-Resistant Strains
Jun 02, 04
16:37 ET	Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences
May 25, 04
07:55 ET	Vertex Pharmaceuticals Announces Plans for the METRO Study: Triple Combination of Merimepodib, Pegasys(R) and Copegus(R) in Hepatitis C Patients
May 24, 04
15:19 ET	Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement
May 06, 04
16:17 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the SunTrust Robinson Humphrey Therapeutics Conference
09:47 ET	Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting
May 04, 04
08:07 ET	Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV
Apr 29, 04
16:09 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at Deutsche Bank's 29th Annual Health Care Conference
Apr 26, 04
16:04 ET	Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress
Apr 16, 04
07:56 ET	Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches
Apr 05, 04
16:05 ET	Vertex Pharmaceuticals Announces the Date of its First Quarter 2004 Financial Results Conference Call and Webcast
Mar 30, 04
08:52 ET	Vertex Pharmaceuticals Nominates John F. Niblack, Ph.D., to its Board of Directors
08:51 ET	Vertex Pharmaceuticals Nominates Eve E. Slater, M.D., F.A.C.C, to its Board of Directors
Mar 25, 04
13:27 ET	GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R)
Mar 17, 04
08:31 ET	Paul S. Anderson, Ph.D., Named to Vertex Pharmaceuticals' Scientific Advisory Board
Mar 08, 04
13:13 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the SG Cowen 24th Annual Health Care Conference
Feb 24, 04
09:32 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 6th Annual BIO CEO & Investor Conference
Feb 23, 04
08:05 ET	Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors
Feb 13, 04
13:05 ET	Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange
Feb 11, 04
16:02 ET	Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004
Feb 10, 04
09:28 ET	Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007
Feb 03, 04
16:08 ET	Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
16:05 ET	Vertex and Novartis Amend Drug Discovery and Development Collaboration
Jan 29, 04
12:15 ET	Vertex Researchers Publish Structure of Flt-3 Kinase in Molecular Cell
Jan 20, 04
08:32 ET	Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS)
Jan 12, 04
13:52 ET	Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JPMorgan Healthcare Conference
Dec 17, 03
16:00 ET	OHSU and Vertex Pharmaceuticals to Collaborate on Drug Discovery and Research Programs
08:34 ET	Phase II, 24-Week Results for Vertex's Merimepodib Presented at the Annual HEP DART Conference
Dec 04, 03
08:25 ET	Telegraph Hill Partners Acquires Instrumentation Assets of Aurora Instruments LLC from Vertex Pharmaceuticals
Nov 20, 03
08:31 ET	Vertex Pharmaceuticals to Webcast its 2003 Investor Day Program
Nov 10, 03
16:07 ET	Vertex Pharmaceuticals Reports Third Quarter 2003 Financial Results
16:05 ET	Vertex Pharmaceuticals to Develop and Commercialize New Treatment for Hepatitis C Virus (HCV) Infection
16:04 ET	Aventis and Vertex Pharmaceuticals Voluntarily Discontinue Phase IIb Clinical Trials of Pralnacasan in Rheumatoid Arthritis
Nov 07, 03
19:15 ET	Vertex Pharmaceuticals Secures Hepatitis C License Agreement from Chiron Corporation
Oct 27, 03
16:05 ET	Research Findings Suggest Potent Antiviral Activity and Favorable In Vitro Resistance Profile for Vertex's Investigational HCV Protease Inhibitor VX-950
Oct 21, 03
09:23 ET	FDA Approves New Protease Inhibitor, Lexiva(TM), the Only Protease Inhibitor to Offer Flexible Dosing with No Food or Water Restrictions
Oct 17, 03
08:06 ET	Vertex Pharmaceuticals Reports Six-Month Results from Phase II Clinical Study of Merimepodib (VX-497) in HCV
Oct 10, 03
08:36 ET	Vertex Pharmaceuticals Announces the Date of its Third Quarter 2003 Financial Results Conference Call and Webcast
Sep 16, 03
14:30 ET	Pharmacokinetic Data Presented at ICAAC on Investigational HIV Protease Inhibitor 433908 (908) Suggest It Can Be Taken with Maalox TC, Zantac, or Lipitor
Jul 24, 03
16:12 ET	Vertex Reports Preliminary 48-Week Data from Phase III Study of 433908, an Investigational HIV Protease Inhibitor
15:45 ET	Vertex Pharmaceuticals Reports Second Quarter 2003 Financial Results Company on Track to Achieve 2003 Goals
Jul 21, 03
07:49 ET	Vertex Pharmaceuticals Announces the Appointment of Dr. Peter Mueller as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation
Jul 14, 03
08:04 ET	Investigational HIV Protease Inhibitor 640385 (VX-385) Combats Resistance
08:03 ET	Resistance Data Presented on GlaxoSmithKline and Vertex's Investigational Protease Inhibitor, 433908
Jul 10, 03
08:30 ET	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2003 Financial Results Conference Call and Webcast
01:45 ET	Aventis and Vertex Pharmaceuticals Announce Start of Enrollment into Phase IIb Clinical Trial for Pralnacasan in Rheumatoid Arthritis
Jun 11, 03
16:00 ET	Data Presented Regarding Viral Mutation Patterns of Unboosted 908
Jun 10, 03
12:45 ET	Vertex Pharmaceuticals Announces Restructuring; Company Prepares for Development and Commercialization of its Innovative Medicines
Jun 09, 03
16:00 ET	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Goldman Sachs Global Healthcare Conference
May 21, 03
09:43 ET	Vertex Pharmaceuticals Provides Update on Clinical Pipeline at Annual Meeting of Shareholders
Apr 24, 03
16:12 ET	Vertex Pharmaceuticals Reports First Quarter 2003 Financial Results
Apr 14, 03
08:38 ET	Vertex Pharmaceuticals Announces the Date of its First Quarter 2003 Financial Results Conference Call and Webcast
Mar 31, 03
07:30 ET	Invitrogen Acquires Products and Technology Rights of PanVera LLC from Vertex Pharmaceuticals
Mar 19, 03
16:30 ET	Vertex Pharmaceuticals Announces the Webcast of Its Corporate Presentation at SG Cowen's 23rd Annual Health Care Conference
Feb 14, 03
09:01 ET	24-Week Data from the CONTEXT Trial Comparing GW433908/Ritonavir QD and BID to Lopinavir/Ritonavir BID in Treatment-Experienced Patients
08:45 ET	Phase III, 48-Week NEAT Study Results Comparing GW433908 (908) to Nelfinavir Presented Today
Feb 11, 03
15:30 ET	48-Week Resistance Data Comparing GW433908, Boosted and Unboosted, With Nelfinavir in Treatment-Naive HIV+ Patients
Feb 04, 03
16:03 ET	Vertex Pharmaceuticals Reports Full Year 2002 Financial Results Company Outlines Financial Guidance and Strategy for 2003
09:02 ET	Invitrogen to Acquire Products and Technology Rights of PanVera LLC from Vertex Pharmaceuticals
Feb 03, 03
08:32 ET	Vertex Pharmaceuticals Announces the Appointment of Ms. Louise Henry as Vice President, Quality
08:31 ET	Vertex Pharmaceuticals Announces the Appointment of Mr. Mark Enyedy as Vice President, Business Development
Jan 06, 03
08:33 ET	Vertex Pharmaceuticals Provides Corporate Update
Jan 03, 03
08:31 ET	Vertex Pharmaceuticals Announces the Date of its Year End 2002 Financial Results Conference Call and Webcast
Jan 02, 03
16:00 ET	Vertex Pharmaceuticals Restructures Agreement with Eli Lilly; Vertex to Lead Development of Novel Oral Hepatitis C Protease Inhibitor VX-950
Dec 20, 02
11:19 ET	Vertex Pharmaceuticals Announces Submission of NDA/MAA Filings in U.S. And Europe for GW433908 for Treatment of HIV Infection
Dec 19, 02
08:31 ET	Vertex Pharmaceuticals Announces Initiation of Phase II Clinical Development of VX-148 in Psoriasis Patients
Nov 21, 02
06:01 ET	48-Week Results for the SOLO Trial Comparing GW433908/R QD to Nelfinavir BID: Presented at International HIV Meeting
Nov 18, 02
07:31 ET	Vertex Pharmaceuticals Provides Update on Progress Toward Pipeline and Corporate Objectives at Fourth Annual Investor Day
Nov 13, 02
08:03 ET	Vertex Advances Aurora Kinase Inhibitor into Preclinical Development Targeting Cancer
07:59 ET	Vertex Researchers Solve 3-D Atomic Structure of Aurora-2 Kinase, Potential Target for New Cancer Treatments; Report in Journal of Biological Chemistry
Nov 11, 02
08:59 ET	Vertex Pharmaceuticals to Webcast its Fourth Annual Investor Day
Nov 04, 02
16:01 ET	Vertex Pharmaceuticals Reports Third Quarter 2002 Financial Results Company on Track to Accomplish Research and Development Milestones
Oct 29, 02
08:59 ET	Phase IIa Clinical Trial Results for Pralnacasan in Rheumatoid Arthritis Presented at ACR
Oct 23, 02
16:01 ET	Vertex Pharmaceuticals Provides Update on GW433908 (908; VX-175) Clinical Development Program
Oct 15, 02
08:36 ET	Vertex Pharmaceuticals Announces the Date of its Third Quarter 2002 Financial Results Conference Call and Webcast
Sep 27, 02
14:00 ET	Phase III, 24-Week Results for the NEAT Trial Comparing GW433908 (908) to Nelfinavir: Presented At ICAAC
Jul 18, 02
16:04 ET	Vertex Pharmaceuticals Reports Second Quarter and First Half 2002 Financial Results
Jul 02, 02
08:34 ET	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2002 Financial Results Conference Call and Webcast
Jun 17, 02
12:48 ET	Vertex Pharmaceuticals Announces Webcast of its Pipeline Update Presentation
Jun 12, 02
08:32 ET	Vertex Pharmaceuticals Announces Start of Clinical Development of VX-702, p38 MAP Kinase Inhibitor for Inflammatory Diseases
May 17, 02
10:20 ET	Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals
Apr 24, 02
16:04 ET	Vertex Pharmaceuticals Reports First Quarter 2002 Financial Results Company Reports Significant Progress Across Product Pipeline
07:03 ET	Aventis Pharma and Vertex Pharmaceuticals to Expand Development of Pralnacasan, Oral Cytokine Inhibitor for Inflammatory Diseases
Apr 11, 02
10:00 ET	Vertex Pharmaceuticals Announces the Date of its First Quarter 2002 Financial Results Conference Call and Webcast
Apr 09, 02
08:37 ET	Vertex Announces Appointment of Tony Coles as Senior Vice President, Commercial Operations-Pharmaceutical Products
Mar 14, 02
08:32 ET	Vertex Pharmaceuticals Appoints Michael G. Wokasch as President of Aurora Biosciences
Feb 21, 02
08:31 ET	Vertex Pharmaceuticals Announces New Responsibilities in Integrated Worldwide Research Organization
Feb 07, 02
16:00 ET	Vertex Pharmaceuticals Reports Year End 2001 Financial Results
Jan 15, 02
08:32 ET	Vertex Pharmaceuticals Announces the Date of Its Fourth Quarter and Year End 2001 Financial Results Conference Call and Webcast
Jan 08, 02
08:04 ET	Vertex Pharmaceuticals Advances New Drug Candidate, VX-799, Into Development to Treat Sepsis
08:04 ET	Vertex Pharmaceuticals Provides Corporate Update and Outlook for 2002
Jan 07, 02
08:08 ET	Lilly and Vertex Pharmaceuticals Select Novel Oral Anti-Hepatitis C Compound
Jan 03, 02
16:00 ET	Aurora Biosciences Signs Assay Development and Screening Collaboration with Allergan
Oct 29, 01
08:29 ET	Vertex Pharmaceuticals Announces the Appointment of Ian F. Smith as Vice President and Chief Financial Officer
Oct 24, 01
16:03 ET	Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results
Oct 03, 01
16:35 ET	Vertex Pharmaceuticals Announces the Appointment of Kenneth Boger as Senior Vice President and General Counsel
16:30 ET	Vertex Pharmaceuticals Announces the Date of its Third Quarter 2001 Financial Results Conference Call and Webcast
Sep 24, 01
07:03 ET	Vertex Moves to Re-allocate Resources from VX-745 in p38 MAP Kinase Program to Accelerate Development of Second Generation Drug Candidates VX-702 and VX-850
Aug 13, 01
08:39 ET	Vertex Pharmaceuticals Installs State-of-the-Art Supercomputer to Accelerate Drug Discovery
Jul 26, 01
16:22 ET	Vertex Pharmaceuticals Reports Second Quarter and First Half 2001 Financial Results
Jul 23, 01
08:38 ET	Michael G. Wokasch Appointed President of PanVera Corporation
Jul 18, 01
18:47 ET	Vertex Pharmaceuticals Announces the Completion of its Acquisition of Aurora Biosciences
Jul 06, 01
08:03 ET	Vertex Pharmaceuticals and Aurora Biosciences Receive Hart-Scott-Rodino Clearance
Jun 27, 01
08:35 ET	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2001 Financial Results Conference Call and Webcast
08:30 ET	Vertex Researchers Solve 3-D Atomic Structure of GSK3 beta Enzyme, Potential Target for New Diabetes Treatments
Jun 20, 01
08:31 ET	Vertex Announces Appointment of Steven I. Engel as Vice President, Regulatory Affairs
Jun 08, 01
14:16 ET	Vertex Pharmaceuticals and Aurora Biosciences Announce Registration Statement For Their Proposed Merger Declared Effective by the SEC
May 24, 01
08:31 ET	Vertex Pharmaceuticals to Webcast its Third Annual Investor Day
May 08, 01
09:42 ET	Vertex Pharmaceuticals Reports Results of Annual Meeting of Shareholders
Apr 30, 01
06:30 ET	Vertex Pharmaceuticals to Acquire Aurora Biosciences
Apr 24, 01
08:07 ET	Vertex Pharmaceuticals Reports First Quarter 2001 Financial Results
Feb 22, 01
07:55 ET	Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2000 Financial Results
Feb 06, 01
17:30 ET	Vertex Pharmaceuticals Reports Preliminary Data from Phase II Clinical Study of VX-175
Jan 31, 01
08:41 ET	Vertex Pharmaceuticals Announces Expansion of Responsibilities in Business Organization
Jan 16, 01
08:29 ET	Vertex Receives Patent for Drug Discovery Targeting Kinase Gene Family
Jan 09, 01
08:32 ET	Vertex Pharmaceuticals Provides Investors with Outlook for 2001
Jan 04, 01
08:35 ET	Vertex Pharmaceuticals Announces Senior Management Promotions in Research Organization
08:31 ET	Vertex Pharmaceuticals Announces Start of Phase II Clinical Trial of VX-745 for Rheumatoid Arthritis
Dec 19, 00
08:29 ET	Vertex Announces Start of Clinical Development with VX-148
Dec 18, 00
09:01 ET	Vertex Announces Senior Management Promotions
Dec 12, 00
07:00 ET	Vertex and Serono Establish Collaboration to Develop and Market Caspase Inhibitors for the Treatment of Neurological and Inflammatory Diseases
Dec 05, 00
09:11 ET	Vicki L. Sato Promoted to President of Vertex Pharmaceuticals
Nov 27, 00
08:29 ET	VX-175, Vertex and Glaxo Wellcome's HIV Protease Inhibitor, Begins Phase III Clinical Trials
Oct 24, 00
16:14 ET	Vertex Pharmaceuticals Reports Third Quarter and First Nine Months of 2000 Financial Results
Oct 23, 00
09:59 ET	Vertex and Glaxo Wellcome's New Anti-HIV Medicine, Agenerase(TM) (Amprenavir), Approved in the European Union
08:41 ET	Vertex Expands Product Pipeline with Selection of Four New Drug Candidates Targeting Viral Infections, Autoimmune and Inflammatory Diseases, and Cardiovascular Disorders
Oct 02, 00
08:54 ET	Vertex Pharmaceuticals Receives U.S. Patent Covering Assay Technology to Accelerate Drug Discovery Targeting Hepatitis C Protease
Sep 19, 00
08:49 ET	Vertex Pharmaceuticals Announces Exercise of Overallotment by Underwriters
Sep 15, 00
15:21 ET	Vertex Pharmaceuticals Calls for Redemption of Convertible Subordinated Notes Due March 2007
Sep 13, 00
18:23 ET	Vertex Pharmaceuticals Raises $300 Million in Convertible Subordinated Debt Placement
Sep 08, 00
16:05 ET	Vertex Pharmaceuticals Announces $200 Million Private Offering of Convertible Subordinated Notes
16:01 ET	Vertex Pharmaceuticals Announces its Intention to Redeem its 5% Convertible Subordinated Notes Due 2007
Jul 25, 00
16:15 ET	Vertex Pharmaceuticals Reports Second Quarter and First Half 2000 Financial Results
Jul 14, 00
10:06 ET	Vertex Pharmaceuticals Announces Two-for-One Stock Split
Jul 11, 00
09:15 ET	Study of Agenerase Combined With Low-dose Ritonavir in PI-experienced Patients
Jul 06, 00
16:16 ET	Vertex Pharmaceuticals Reports Preliminary Results for the Second Quarter of 2000
Jul 03, 00
08:42 ET	Vertex Begins Phase II Study of VX-497 in Combination with Interferon Alpha For Treatment of Hepatitis C Infection
Jun 30, 00
11:30 ET	European CPMP Gives Positive Opinion on Market Approval for Glaxo Wellcome and Vertex's Twice-Daily Treatment For HIV, Agenerase(TM)
May 24, 00
08:33 ET	Vertex Receives $10 Million Payment from Aventis Pharma for Drug Candidates Targeting Inflammatory Diseases
May 11, 00
16:15 ET	Vertex Pharmaceuticals Reports First Quarter 2000 Financial Results
May 09, 00
05:59 ET	Vertex and Novartis Establish Discovery Alliance Targeting Protein Kinases -Agreement Pioneers New Model for Drug Discovery and Early Development-
Apr 10, 00
08:29 ET	Vertex to Access Genomic and Proteomic Technologies in Alliance With Harvard Medical School
Mar 09, 00
08:42 ET	Vertex Pharmaceuticals Raises $175 Million in Convertible Subordinated Debt Placement
Mar 03, 00
11:59 ET	Vertex Pharmaceuticals Announces $200 Million Private Offering Of Convertible Subordinated Notes
Feb 29, 00
08:38 ET	Incyte and Vertex Enter Genomic Partnership to Accelerate Drug Discovery in Multi-target Gene Families Using LifeSeq Gold
Feb 16, 00
16:32 ET	Vertex Pharmaceuticals Reports 1999 Fourth Quarter And Year End Financial Results
Dec 16, 99
08:57 ET	VX-175/GW433908, Vertex and Glaxo Wellcome HIV Protease Inhibitor In Clinical Development, Receives Fast Track Designation from U.S. FDA
Dec 09, 99
08:44 ET	Vertex Announces Appointment of Dr. Neil Kirby As HIV Program Executive
Nov 29, 99
09:30 ET	Vertex and Taisho Establish Collaboration to Develop Caspase Inhibitors for Cerebrovascular, Cardiovascular and Neurodegenerative Diseases
Nov 18, 99
12:06 ET	Vertex Reports Phase II Clinical Data on Incel (TM) for Treatment of Advanced Hormone-Refractory Prostate Cancer
12:06 ET	Vertex Reports Phase II Interim Analysis Clinical Data on Incel(TM) for Treatment of Chemotherapy-Resistant Ovarian Cancer
Nov 08, 99
16:01 ET	Vertex Reports VX-497 Phase II Clinical Data for Hepatitis C Virus Infection
Nov 02, 99
08:44 ET	Vertex Begins Pilot Phase II Clinical Trial of VX-745, p38 MAP Kinase Inhibitor for the Treatment of Inflammatory Disease
Oct 26, 99
16:15 ET	Vertex Pharmaceuticals Reports 1999 Third Quarter And Nine Month Financial Results
Oct 19, 99
16:13 ET	Vertex Announces Hart-Scott-Rodino Clearance for Expanded Agreement With Hoechst Marion Roussel
Sep 30, 99
08:29 ET	Vertex Partner Kissei Pharmaceutical to Launch HIV Protease Inhibitor Prozei(TM) in Japan
Sep 28, 99
16:30 ET	Immune Response Resulting from Treatment With Agenerase(TM) + Ziagen(R) Evaluated in Patients with Early Stage HIV Infection
Sep 27, 99
14:43 ET	Data Presented at Medical Conference on VX-175/GW433908, An HIV Protease Inhibitor Prodrug
08:43 ET	48-Week Results from Pivotal Agenerase(TM) Study Presented
08:42 ET	Cross-Resistance to Agenerase(TM) and Other Protease Inhibitors Assessed in Patients with Previous PI Experience
Sep 16, 99
10:17 ET	Vertex Announces Start of Phase II Clinical Trial of HMR 3480/VX-740 for Treatment of Rheumatoid Arthritis
Sep 01, 99
15:02 ET	Hoechst Marion Roussel and Vertex Expand Agreement to Develop Novel Anti-Inflammatory Compounds
Jul 29, 99
08:34 ET	Vertex Neurophilin Ligands Demonstrate Neuroprotective Effect in Models of Parkinson's Disease
Jul 27, 99
16:05 ET	Vertex Pharmaceuticals Reports Second Quarter 1999 Financial Results
Jul 12, 99
14:45 ET	Improved Nerve Function Demonstrated in Preclinical Tests of Vertex's Investigational Neurophilin Compounds
Jul 02, 99
08:57 ET	Kissei Pharmaceutical Files for Approval of HIV Protease Inhibitor in Japan
Jun 23, 99
11:41 ET	Newest HIV Protease Inhibitor Agenerase(TM) Now Available in Oral Solution
May 18, 99
08:31 ET	Vertex Reports Phase II Clinical Data on Incel(TM) for Treatment of Chemotherapy-Resistant Soft Tissue Sarcoma
Apr 21, 99
16:17 ET	Vertex Pharmaceuticals Reports First Quarter 1999 Financial Results
Apr 16, 99
13:29 ET